KLK3 and prostate carcinoma: In contrast, in the GS 6–7 group, only patients with T1 stage prostate cancer and PSA ≤ 4 ng/mL were found to have a better survival (HR, 0.91; 95% CI [0.85–0.97]; P = 0.005).